title: Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.
abstract: BACKGROUND
  We have previously shown that (+/-)-3,4-methylenedioxymethamphetamine (MDMA) treatment from postnatal days (P)11 to P20 leads to learning and memory deficits when the animals are tested as adults. Recently, the club drug 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) has gained popularity.
  
  
  OBJECTIVE
  Due to the similarities between MDMA and 5-MeO-DIPT and the substitution of 5-MeO-DIPT for MDMA, the purpose of this study was to compare the developmental effects of these drugs.
  
  
  METHODS
  Within a litter, animals were treated from P11 to P20 with either MDMA, 5-MeO-DIPT, or saline.
  
  
  RESULTS
  MDMA-treated animals showed increased anxiety in a measure of defensive marble burying, as well as deficits in spatial and path integration learning. 5-MeO-DIPT-treated animals showed spatial learning deficits; however, there were no deficits observed in spatial memory or path integration learning. 5-MeO-DIPT-treated animals also showed hyperactivity in response to a challenge dose of methamphetamine.
  
  
  CONCLUSIONS
  The results show that treatment with either 5-MeO-DIPT or MDMA during development results in cognitive deficits and other behavioral changes but the pattern of effects is distinct for each drug.
authors.affiliation: Division of Neurology, Cincinnati Children's Research Foundation and University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Skelton
authors.forename: Tori L
authors.initials: TL
authors.lastname: Schaefer
authors.forename: Nicole R
authors.initials: NR
authors.lastname: Herring
authors.forename: Curtis E
authors.initials: CE
authors.lastname: Grace
authors.forename: Charles V
authors.initials: CV
authors.lastname: Vorhees
authors.forename: Michael T
authors.initials: MT
authors.lastname: Williams
mesh_terms: D000375:Aging / Q000523:psychology*; D000818:Animals; D001007:Anxiety / Q000523:psychology; D001835:Body Weight / Q000187:drug effects; D003463:Cues; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D007858:Learning / Q000187:drug effects; D008029:Lighting; D018782:Maze Learning / Q000187:drug effects; D008568:Memory / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D010111:Oxymorphone / Q000031:analogs & derivatives* / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D006213:Hallucinogens; C042285:6-fluoro-6-desoxyoxymorphone; D010111:Oxymorphone; D018817:N-Methyl-3,4-methylenedioxyamphetamine